Find publications by Adaptive as well as our collaborators and partners who leverage our technologies.



Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

Paulson et al.

  • Nature Communications
  • Papers
  • September 2018

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Hopkins et al.

  • JCI Insight
  • Papers
  • July 2018

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta et al.

  • Nature
  • Papers
  • May 2018

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

Ariyan et al.

  • Cancer Immunology Research
  • Papers
  • April 2018

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Wrangle et al.

  • Lancet Oncology
  • Papers
  • April 2018

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde et al.

  • New England Journal of Medicine
  • Papers
  • April 2018

Combination of ipilimumab and adoptive Cell Therapy with Tumor-infiltrating lymphocytes for Patients with Metastatic Melanoma

Mullinax et al.

  • Frontiers in Oncology
  • Papers
  • March 2018

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Herrera et al.

  • Blood
  • Papers
  • March 2018

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Usmani et al.

  • Experimental Hematology & Oncology
  • Papers
  • February 2018